


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	RILAPLADIB
PRONUNCIATION	ri lap' la dib
THERAPEUTIC CLAIM	Treatment of atherosclerosis

CHEMICAL NAMES

- 1) 1(4*H*)-quinolineacetamide, 2-[[[(2,3-difluorophenyl)methyl]thio]-*N*-[1-(2-methoxyethyl)-4-piperidinyl]-4-oxo-*N*-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-
- 2) 2-[2-[[[(2,3-difluorobenzyl)sulfanyl]-4-oxoquinolin-1(4*H*)-yl]-*N*-[1-(2-methoxyethyl)piperidin-4-yl]-*N*-[[4'-(trifluoromethyl)biphenyl-4-yl]methyl]acetamide

STRUCTURAL FORMULA



MOLECULAR FORMULA	C ₄₀ H ₃₉ F ₅ N ₃ O ₃ S
MOLECULAR WEIGHT	735.8
TRADEMARK	Unknown as yet
MANUFACTURER	GlaxoSmithKline
CODE DESIGNATION	SB-659032
<u>CAS</u> REGISTRY NUMBER	412950-08-4